A phase I/II study of concurrent chemoradiotherapy (RT-DeVIC) for newly-diagnosed, localized nasal NK/T-cell lymphoma (JCOG0211-DI)

Phase 1

• Conditions: extranodal NK/T-cell lymphoma, nasal type

• Registration Number: JPRN-UMIN000007842
• Lead Sponsor: Japan Clinical Oncology Group (JCOG)

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Completion: 2011-12-28
• Study Start: 2012-04-27
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Complete: follow-up complete
• Sex: All
• Target Recruitment: 33

Inclusion Criteria

Not provided

Exclusion Criteria

1) Clinical symptoms of Central nervous system involvement 2) Uncontrollable diabetes mellitus 3) Uncontrollable hypertension 4) History of myocardial infarction or angina, and/or cardiomyopathy, and/or arrhythmia treated with antiarrhythmic 5) Positive test for HBs antigen 6) Positive test for HIV antibody 7) Interstitial pneumonia, pulmonary fibrosis or severe pulmonary emphysema 8) Severe infection 9) Liver cirrhosis 10) Other active malignancies 11) Pregnant, possible pregnant, or breastfeeding woman 12) Use of major tranquilizer, antidepressant, or antimanic 13) Severe psychosis 14) Patients or their families, and/or attending physicians hoping hematopoietic stem cell transplantation after obtained responses by RT-DeVIC

Study & Design

• Study Type: Interventional
• Study Design: Not specified